Synthetic vaccine particles for durable cytolytic T lymphocyte responses and antitumor immunotherapy

Petr O. Ilyinskii, Grigoriy I. Kovalev, Conlin P. O’Neil, Christopher J. Roy, Alicia M. Michaud, Natalia M. Drefs, Mikhail A. Pechenkin, Fen ni Fu, Lloyd P.M. Johnston, Dmitry A. Ovchinnikov, Takashi Kei Kishimoto

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

We previously reported that synthetic vaccine particles (SVP) encapsulating antigens and TLR agonists resulted in augmentation of immune responses with minimal production of systemic inflammatory cytokines. Here we evaluated two different polymer formulations of SVP-encapsulated antigens and tested their ability to induce cytolytic T lymphocytes (CTL) in combination with SVP-encapsulated adjuvants. One formulation led to efficient antigen processing and cross-presentation, rapid and sustained CTL activity, and expansion of CD8+ T cell effector memory cells locally and centrally, which persisted for at least 1–2 years after a single immunization. SVP therapeutic dosing resulted in suppression of tumor growth and a substantial delay in mortality in several syngeneic mouse cancer models. Treatment with checkpoint inhibitors and/or cytotoxic drugs, while suboptimal on their own, showed considerable synergy with SVP immunization. SVP encapsulation of endosomal TLR agonists provided superior CTL induction, therapeutic benefit and/or improved safety profile compared to free adjuvants. SVP vaccines encapsulating mutated HPV-16 E7 and E6/E7 recombinant proteins led to induction of broad CTL activity and strong inhibition of TC-1 tumor growth, even when administered therapeutically 13–14 days after tumor inoculation in animals bearing palpable tumors. A pilot study in non-human primates showed that SVP-encapsulated E7/E6 adjuvanted with SVP-encapsulated poly(I:C) led to robust induction of antigen-specific T and B cell responses.

Original languageEnglish
Article numbere0197694
JournalPLoS ONE
Volume13
Issue number6
DOIs
Publication statusPublished - Jun 2018
Externally publishedYes

Fingerprint

Dive into the research topics of 'Synthetic vaccine particles for durable cytolytic T lymphocyte responses and antitumor immunotherapy'. Together they form a unique fingerprint.

Cite this